We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01578772
First Posted: April 17, 2012
Last Update Posted: December 8, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
The Campbell Foundation
Information provided by (Responsible Party):
Jordan E. Lake M.D., University of California, Los Angeles
Results First Submitted: September 4, 2014  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Endothelial Dysfunction
Intervention: Drug: Telmisartan

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Telmisartan

Open label

Telmisartan: 80mg tablets po daily for 6 weeks


Participant Flow:   Overall Study
    Telmisartan
STARTED   17 
COMPLETED   17 
NOT COMPLETED   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
HIV-infected individual >50 years old with HIV-1 RNA <50 copies /mL on stable ART and >=1 CVD risk factor.

Reporting Groups
  Description
Telmisartan

Open label

Telmisartan: 80mg tablets po daily for 6 weeks


Baseline Measures
   Telmisartan 
Overall Participants Analyzed 
[Units: Participants]
 17 
Age 
[Units: Years]
Median (Inter-Quartile Range)
 60 
 (54 to 63) 
Gender 
[Units: Participants]
 
Female   2 
Male   15 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   6-week Change in Diameter and Flow Mediated Dilatation (FMD) of the Brachial Artery With Telmisartan Therapy   [ Time Frame: 6 weeks (after baseline) ]

2.  Primary:   6-week Change in Maximum Relative Flow Mediated Dilatation (FMD) of the Brachial Artery With Telmisartan Therapy   [ Time Frame: 6 weeks (after baseline) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Given the limited size of the study population, the study was underpowered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Jordan Lake
Organization: UCLA
phone: 310-557-2273
e-mail: jlake@mednet.ucla.edu


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Jordan E. Lake M.D., University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT01578772     History of Changes
Other Study ID Numbers: miFMD
First Submitted: February 1, 2012
First Posted: April 17, 2012
Results First Submitted: September 4, 2014
Results First Posted: December 8, 2014
Last Update Posted: December 8, 2014